Article
Oncology
Elisa Van Raemdonck, G. Floris, P. Berteloot, A. Laenen, I. Vergote, H. Wildiers, K. Punie, P. Neven
Summary: In stage IV breast cancer, the conversion of HER2 status is common and primarily observed in hormone receptor-positive tumors. Patients with a positive-to-negative conversion or negative-to-positive conversion showed significant differences in progression free survival and overall survival compared to patients with consistent HER2 status. This study highlights the importance of re-biopsying metastatic lesions and adjusting treatments based on the latest HER2 results.
BREAST CANCER RESEARCH AND TREATMENT
(2021)
Article
Oncology
Youzhao Ma, Dechuang Jiao, Jingyang Zhang, Minhao Lv, Xiuchun Chen, Zhenzhen Liu
Summary: This study investigated the clinicopathological and prognostic characteristics of HER2-low status in a large sample of early-stage triple-negative breast cancer datasets. The findings suggest that HER2-low breast cancer is associated with better breast cancer-specific survival, especially in high-risk groups.
Article
Oncology
Tatjana Geukens, Maxim De Schepper, Francois Richard, Marion Maetens, Karen Van Baelen, Amena Mahdami, Ha-Linh Nguyen, Edoardo Isnaldi, Sophia Leduc, Anirudh Pabba, Gitte Zels, Freya Mertens, Sara Vander Borght, Ann Smeets, Ines Nevelsteen, Kevin Punie, Patrick Neven, Hans Wildiers, Wouter van den Bogaert, Giuseppe Floris, Christine Desmedt
Summary: This study evaluated the inter-metastasis heterogeneity of HER2-low status in metastatic breast cancer patients, finding that HER2-low and HER2-negative metastases coexisted in the same patients. This raises questions about the validity of HER2-low as a therapeutic marker.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Ana C. C. Garrido-Castro, Meredith M. M. Regan, Samuel M. M. Niman, Faina Nakhlis, Claire Remolano, Jennifer M. M. Rosenbluth, Caroline Block, Laura E. E. Warren, Jennifer R. R. Bellon, Eren Yeh, Beth T. T. Harrison, Elizabeth Troll, Nancy U. U. Lin, Sara M. M. Tolaney, Beth Overmoyer, Filipa Lynce
Summary: Inflammatory breast cancer (IBC) is a rare and aggressive form of breast cancer, presenting as de novo metastatic disease in a significant portion of cases. Limited research has been conducted on the utilization of locoregional therapy after HER2-directed systemic therapy in these patients, as well as their locoregional progression and survival outcomes. A study identified patients with de novo HER2-positive metastatic IBC and evaluated their treatment data and outcomes. The findings suggest that surgery after systemic therapy may lead to favorable outcomes, with good locoregional control and prolonged survival observed.
Article
Oncology
I-Chun Chen, Fu-Chang Hu, Ching-Hung Lin, Shu-Min Huang, Dwan-Ying Chang, Ann-Lii Cheng, Yen-Shen Lu
Summary: The meta-analysis results revealed that in patients with HER2-positive metastatic breast cancer, treatment with anti-HER2 antibodies led to a prolongation of OS more than PFS, with the absolute increment in median OS time being double that of median PFS time, and this increase was linearly correlated, indicating the need for further investigation into the efficacy of anti-HER2 antibodies.
Article
Oncology
Aki Uutela, Emerik Osterlund, Paivi Halonen, Raija Kallio, Annika Algars, Tapio Salminen, Annamarja Lamminmaki, Leena-Maija Soveri, Raija Ristamaki, Kaisa Lehtomaki, Hanna Stedt, Eetu Heerva, Timo Muhonen, Juha Kononen, Arno Nordin, Ali Ovissi, Soili Kytola, Mauri Keinanen, Jari Sundstrom, Lasse Nieminen, Markus J. Makinen, Teijo Kuopio, Ari Ristimaki, Helena Isoniemi, Pia Osterlund
Summary: RAS and BRAF mutational status significantly influence the resectability, conversion rates, and resection/LAT rates of metastasectomy for metastatic colorectal cancer (mCRC). Patients with RAS and BRAF wild-type have significantly longer overall survival (OS) compared to mutant patients. Systemic therapy-only patients have poorer long-term survival, with variation according to molecular status.
BRITISH JOURNAL OF CANCER
(2022)
Article
Oncology
Tiia J. Honkanen, Milla E. K. Luukkainen, Antti Tikkanen, Peeter Karihtala, Markus Makinen, Juha P. Vayrynen, Jussi P. Koivunen
Summary: Recent studies have shown that the site of metastasis can impact the immune characteristics of tumors and the effectiveness of cancer immunotherapies. In HER2-positive breast cancer patients, liver metastases are associated with poor prognosis, while pulmonary metastases show a trend towards improved survival. Liver metastases are also linked to adverse tumor immune cell profiles, with lower densities of CD3(+) T cells and M1-like macrophages in primary tumors.
BREAST CANCER RESEARCH AND TREATMENT
(2022)
Article
Oncology
Angel Guerrero-Zotano, Stefania Belli, Christoph Zielinski, Miguel Gil-Gil, Antonio Fernandez-Serra, Manuel Ruiz-Borrego, Eva Maria Ciruelos Gil, Javier Pascual, Montserrat Munoz-Mateu, Begon Bermejo, Mireia Margeli Vila, Antonio Anton, Laura Murillo, Bella Nissenbaum, Yuan Liu, Jesus Herranz, Daniel Fernandez-Garcia, Rosalia Caballero, Jose Antonio Lopez-Guerrero, Roberto Bianco, Luigi Formisano, Nicholas Turner, Miguel Martin
Summary: In patients with hormone receptor-positive (HR+)/HER2- metastatic breast cancer, non-luminal subtype and high CCNE1 expression are associated with resistance to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) and poor response to treatment. Furthermore, high levels of the Polo-like kinase 1 (PLK1) mRNA indicate resistance to palbociclib, suggesting that PLK1 may play a role in CDK4/6i resistance. These findings highlight the need for validation of these biomarkers and the exploration of PLK1 as a therapeutic target.
CLINICAL CANCER RESEARCH
(2023)
Article
Multidisciplinary Sciences
Izzet Dogan, Esra Aydin, Nijat Khanmammadov, Nail Paksoy, Pinar Saip, Adnan Aydiner
Summary: The purpose of this study was to evaluate the prognosis and predictors of complete response for HER2-positive metastatic breast cancer patients receiving long-term trastuzumab-based therapy. Binary regression analysis was used to analyze the predictors of complete response. A total of 80 patients were included in the study, with a median trastuzumab treatment duration of 62 months. A complete response was observed in 75% of patients, with a median duration of 14.8 months. Menopausal status, the number of metastatic sites, and the use of endocrine therapy with trastuzumab were found to be significant predictors of complete response. The study highlights the potential of trastuzumab-based therapy for achieving complete cure in HER2-positive metastatic breast cancer patients, but further multicenter studies are needed to confirm these findings.
SCIENTIFIC REPORTS
(2023)
Article
Oncology
Yuqin Yang, Liudan Li, Wenjing Tian, Zhen Qiao, Qi Qin, Liqian Su, Peiqiu Li, Weirong Chen, Hong Zhao
Summary: In breast cancer patients with HER2-negative tumors, HER2-positive circulating tumor cells were associated with the effectiveness of HER2-targeted therapy. A model was developed to predict cHER2 status, and uric acid and De Ritis ratio were found to be significantly associated with cHER2 status, affecting patients' disease-free survival.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Karen A. Gelmon, Peter A. Fasching, Fergus J. Couch, Judith Balmana, Suzette Delaloge, Intidhar Labidi-Galy, James Bennett, Susan McCutcheon, Graham Walker, Joyce O'Shaughnessy
Summary: The study evaluated the clinical effectiveness of olaparib in patients with gBRCAm, showing a significant increase in progression-free survival and consistent safety outcomes compared with previous findings.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Oncology
S. J. Seung, H. Saherawala, D. Moldaver, S. Shokar, C. Ammendolea, C. Brezden-Masley
Summary: This study investigated survival, treatment patterns, and costs in HER2-positive metastatic breast cancer patients in Ontario. The results showed that pertuzumab and trastuzumab were the most frequently used treatment regimens in early-stage metastatic breast cancer, while T-DM1 was the most common therapy in the second line. Treatment costs were mainly driven by the cost of systemic therapy and cancer clinic visits.
BREAST CANCER RESEARCH AND TREATMENT
(2023)
Article
Oncology
J. -S. Frenel, A. Lusque, S. Delaloge, J. -M. Ferrero, T. Bachelot, I. Desmoulins, C. Levy, J. -C. Eymard, A. Goncalves, A. Patsouris, M. A. Mouret Reynier, M. J. -C. Thery, T. Petit, L. Cabel, L. Uwer, M. Debled, M. Chevrot, A. Mailliez, W. Jacot, T. de la Motte Rouge
Summary: The efficacy of endocrine therapy in HR+/HER2- metastatic breast cancer could be influenced by the presence of BRCA1/2 germline mutation. In this study, it was found that patients with gBRCAm mutation had lower overall survival and first-line progression-free survival after first-line endocrine therapy, but no difference was observed in patients who received first-line chemotherapy.
BRITISH JOURNAL OF CANCER
(2023)
Article
Oncology
V Mueller, M. Banys-Paluchowski, T. W. P. Friedl, P. A. Fasching, A. Schneeweiss, A. Hartkopf, D. Wallwiener, B. Rack, F. Meier-Stiegen, J. Huober, M. Ruebner, O. Hoffmann, L. Mueller, W. Janni, P. Wimberger, B. Jaeger, K. Pantel, S. Riethdorf, N. Harbeck, T. Fehm
Summary: CTC detection is a strong prognostic factor in patients with HER2-negative breast cancer. The presence of >= 1 CTC with strong HER2 staining is associated with shorter overall survival.ER and PR positive tumor patients are more likely to harbor CTCs with strong HER2 staining.
Article
Multidisciplinary Sciences
Alma Andersson, Ludvig Larsson, Linnea Stenbeck, Fredrik Salmen, Anna Ehinger, Sunny Z. Wu, Ghamdan Al-Eryani, Daniel Roden, Alex Swarbrick, Ake Borg, Jonas Frisen, Camilla Engblom, Joakim Lundeberg
Summary: This study utilized Spatial Transcriptomics technology to investigate gene expression in HER2-positive breast tumors, identifying shared gene signatures for immune and tumor processes and developing a predictive model for cellular interactions.
NATURE COMMUNICATIONS
(2021)
